Advertisement

Nierenzellkarzinome

  • Jochen Decker
  • Hiltrud Brauch
Chapter
Part of the Molekulare Medizin book series (MOLMED)

Zusammenfassung

Das Nierenzellkarzinom wurde bereits im frühen 19. Jahrhundert beschrieben und sein Ursprung dem tubulären Epithel zugeordnet. Zunächst setzte sich, aufbauend auf den Arbeiten von Grawitz (1883), die Lehrmeinung durch, dass das Nierenzellkarzinom aus ektopen adrenalen Zellen im Nierengewebe abzuleiten sei, da sich die Karzinomzellen in ihrem Fettgehalt nicht von Zellen der Nebenniere unterscheiden (Grawitz 1883). In der älteren Literatur wird daher das Nierenzellkarzinom auch als Grawitz-Tumor oder hypernephroides Karzinom bezeichnet (Grawitz 1883). Auch der Begriff des Hypernephroms wurde in diesem Zusammenhang geprägt und findet sich fortan zwar konzeptionell falsch, aber dennoch nachhaltig auch heute noch in Lehrbüchern.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Adryan B, Decker HJ, Papas TS, Hsu T (2000) Tracheal development and the von Hippel-Lindau tumor suppressor homolog in Drosophila. Oncogene 19:2803–2811PubMedGoogle Scholar
  2. Anglard P, Tory K, Brauch H et al. (1991) Molecular analysis of genetic changes in the origin and development of renal cell carcinoma. Cancer Res 51:1071–1077PubMedGoogle Scholar
  3. Atlas I, Mendelsohn J, Baselga J, Fair WR, Masui H, Kumar R (1992) Growth regulation of human renal carcinoma cells: role of transforming growth factor alpha. Cancer Res 52:3335–3339PubMedGoogle Scholar
  4. Becker N, Wahrendorf J (1998) Atlas of cancer mortality in the Federal Republic of Germany 1981-1990, 3rd edn. Springer, Berlin Heidelberg New YorkGoogle Scholar
  5. Berg WJ, Divgi CR, Nanus DM, Motzer RJ (2000) Novel investigative approaches for advanced renal cell carcinoma. Semin Oncol 27:234–239PubMedGoogle Scholar
  6. Bernauer U, Birner G, Dekant W, Henschler D (1996) Biotransformation of trichloroethene: dose-dependent excretion of 2,2,2-trichloro-metabolites and mercapturic acids in rats and humans after inhalation. Arch Toxicol 70:338–346PubMedGoogle Scholar
  7. Bernues M, Casadevall C, Miro R et al. (1995) Cytogenetic characterization of a familial papillary renal cell carcinoma. Cancer Genet Cytogenet 84:123–127PubMedGoogle Scholar
  8. Beroud C, Joly D, Gallou C, Staroz F, Orfanelli MT, Junien C (1998) Software and database for the analysis of mutations in the VHL gene. Nucleic Acids Res 26:256–258PubMedCentralPubMedGoogle Scholar
  9. Beroud C, Collod-Beroud G, Boileau C, Soussi T, Junien C (2000) UMD (Universal mutation database): a generic software to build and analyze locus-specific databases. Hum Mutat 15:86–94PubMedGoogle Scholar
  10. Bjornsson J, Short MP, Kwiatkowski DJ, Henske EP (1996) Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am J Pathol 149:1201–1208PubMedCentralPubMedGoogle Scholar
  11. Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C (1995) Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376:768–771PubMedGoogle Scholar
  12. Biom JH, Poppel H van, Marechal JM et al. (1999) Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. Eur Urol 36:570–575Google Scholar
  13. Bonicalzi ME, Groulx I, Paulsen N de, Lee S (2001) Role of exon 2-encoded beta-domain of the von Hippel-Lindau tumor suppressor protein. J Biol Chem 276:1407–1416PubMedGoogle Scholar
  14. Boring CC, Squires TS, Tong T, Montgomery S (1994) Cancer statistics, 1994. CA Cancer J Clin 44:7–26PubMedGoogle Scholar
  15. Bourneville D (1880) Sclereuse tubereuse des circonvolutions cerebrales. Idiote et epilepsie hemiplegique. Arch Neurol (Paris) 1:81Google Scholar
  16. Brauch H, Pomer S, Hieronymus T, Schadt T, Lohrke H, Komitowski D (1994) Genetic alterations in sporadic renal cell carcinoma: molecular analyses of tumor suppressor gene harboring chromosomal regions 3p, 5q, and 17p.World J Urol 12:162–168PubMedGoogle Scholar
  17. Brauch H, Kishida T, Glavac D et al. (1995) Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect. Hum Genet 95:551–556PubMedGoogle Scholar
  18. Brauch H, Weirich G, Hornauer MA, Storkel S, Wohl T, Bruning T (1999) Trichloroethylene exposure and specific somatic mutations in patients with renal cell carcinoma. J Natl Cancer Inst 91:854–861PubMedGoogle Scholar
  19. Brauch H, Weirich G, Brieger J et al. (2000) VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res 60:1942–1948PubMedGoogle Scholar
  20. Braybrooke JP, Vallis KA, Houlbrook S et al. (2000) Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine. Cancer Chemother Pharmacol 46:27–34PubMedGoogle Scholar
  21. Brieger J, Weidt EJ, Schirmacher P, Storkel S, Huber C, Decker HJ (1999) Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in sporadic renal cell carcinomas is correlated with vascular growth: an in vivo study on 29 tumors. J Mol Med 77:505–510PubMedGoogle Scholar
  22. Bruning T, Bolt HM (2000) Renal toxicity and carcinogen-city of trichloroethylene: key results, mechanisms, and controversies. Crit Rev Toxicol 30:253–285PubMedGoogle Scholar
  23. Bruning T, Lammert M, Kempkes M, Thier R, Golka K, Bolt HM (1997) Influence of polymorphisms of GSTM1 and GSTT1 for risk of renal cell cancer in workers with longterm high occupational exposure to trichloroethene. Arch Toxicol 71:596–599PubMedGoogle Scholar
  24. Bruning T, Vamvakas S, Makropoulos V, Birner G (1998) Acute intoxication with trichloroethene: clinical symptoms, toxicokinetics, metabolism, and development of biochemical parameters for renal damage. Toxicol Sci 41:157–165PubMedGoogle Scholar
  25. Bugert P, Gaul C, Weber K et al. (1997) Specific genetic changes of diagnostic importance in chromophobe renal cell carcinomas. Lab Invest 76:203–208PubMedGoogle Scholar
  26. Cairns P, Tokino K, Eby Y, Sidransky D (1995) Localization of tumor suppressor loci on chromosome 9 in primary human renal cell carcinomas. Cancer Res 55:224–227PubMedGoogle Scholar
  27. Campbell SC, Novick AC (1994) Management of local recurrence following radical nephrectomy or partial nephrectomy. Urol Clin North Am 21:593–599PubMedGoogle Scholar
  28. Cavenee WK, Dry ja TP, Phillips RA et al. (1983) Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305:779–784PubMedGoogle Scholar
  29. Chen F, Kishida T, Duh FM et al. (1995a) Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. Cancer Res 55:4804–4807PubMedGoogle Scholar
  30. Chen F, Kishida T, Yao M et al. (1995b) Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 5:66–75PubMedGoogle Scholar
  31. Chen F, Slife L, Kishida T, Mulvihill J, Tisherman SE, Zbar B (1996) Genotype-phenotype correlation in von HippelLindau disease: identification of a mutation associated with VHL type 2A. J Med Genet 33:716–717PubMedCentralPubMedGoogle Scholar
  32. Childs R, Chernoff A, Contentin N et al. (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343:750–758PubMedGoogle Scholar
  33. Chung-Park M, Parveen T, Lam M (1989) Acquired cystic disease of the kidneys and renal cell carcinoma in chronic renal insufficiency without dialysis treatment. Nephron 53:157–161PubMedGoogle Scholar
  34. Cockman ME, Masson N, Mole DR et al. (2000) Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275:25733–25741PubMedGoogle Scholar
  35. Cohen AJ, Li FP, Berg S et al. (1979) Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med 301:592–596PubMedGoogle Scholar
  36. Cohen HT, Zhou M, Welsh AM et al. (1999) An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association. Biochem Biophys Res Commun 266:43–50PubMedGoogle Scholar
  37. Collins ET (1894) Intra-ocular growths. Two cases, brother and sister, with pecular vascular new growth, probably primarily retinal, affecting both eyes. Trans Ophthalmol Soc UK 14:141Google Scholar
  38. Comings DE (1973) A general theory of carcinogenesis. Proc Natl Acad Sci USA 70:3324–3328PubMedCentralPubMedGoogle Scholar
  39. Cook RJ, Lawless JF (1996) Interim monitoring of longitudinal comparative studies with recurrent event responses. Biometrics 52:1311–1323PubMedGoogle Scholar
  40. Crossey PA, Richards FM, Foster K et al. (1994) Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet 3:1303–1308PubMedGoogle Scholar
  41. Decker HJ, Neumann HP, Walter TA, Sandberg AA (1988) 3p involvement in a renal cell carcinoma in von Hippel-Lindau syndrome. Region of tumor breakpoint clustering on 3p? Cancer Genet Cytogenet 33:59–65PubMedGoogle Scholar
  42. Decker HJ, Neuhaus C, Jauch A et al. (1996) Detection of a germline mutation and somatic homozygous loss of the von Hippel-Lindau tumor-suppressor gene in a family with a de novo mutation. A combined genetic study, including cytogenetics, PCR/SSCP, FISH, and CGH. Hum Genet 97:770–776PubMedGoogle Scholar
  43. Dekant W, Metzler M, Henschler D (1986a) Identification of S-I,2-dichlorovinyl-N-acetyl-cysteine as a urinary metabolite of trichloroethylene: a possible explanation for its nephrocarcinogenicity in male rats. Biochem Pharmacol 35:2455–2458PubMedGoogle Scholar
  44. Dekant W, Schulz A, Metzler M, Henschler D (1986b) Absorption, elimination and metabolism of trichloroethylene: a quantitative comparison between rats and mice. Xenobiotica 16:143–152PubMedGoogle Scholar
  45. Delahunt B, Eble JN (1997) Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 10:537–544PubMedGoogle Scholar
  46. Divgi CR, Bander NH, Scott AM et al. (1998) Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma.Clin Cancer Res 4:2729–2739PubMedGoogle Scholar
  47. Duan DR, Humphrey JS, Chen DY et al. (1995a) Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. Proc Natl Acad Sci USA 92:6459–6463PubMedCentralPubMedGoogle Scholar
  48. Duan DR, Pause A, Burgess WH et al. (1995b) Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269:1402–1406PubMedGoogle Scholar
  49. Delahunt B, Eble JN (1997) Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 10:537–544PubMedGoogle Scholar
  50. Divgi CR, Bander NH, Scott AM et al. (1998) Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 4:2729–2739PubMedGoogle Scholar
  51. Duan DR, Humphrey JS, Chen DY et al. (1995a) Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. Proc Natl Acad Sci USA 92:6459–6463PubMedCentralPubMedGoogle Scholar
  52. Duan DR, Pause A, Burgess WH et al. (1995b) Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269:1402–1406PubMedGoogle Scholar
  53. Fischer J, Palmedo G, Knobloch R von et al. (1998) Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours. Oncogene 17:733–739PubMedGoogle Scholar
  54. Fleming I.D. (1998) Revision of TNM classification for oropharyngeal carcinoma. Cancer 82:1611–1612PubMedGoogle Scholar
  55. Fossa SD (2000) Interferon in metastatic renal cell carcinoma. Semin Oncol 27:187–193PubMedGoogle Scholar
  56. Foster K, Prowse A, Berg A van den et al. (1994) Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 3:2169–2173PubMedGoogle Scholar
  57. Franksson C, Bergstrand A, Ljungdahl I, Magnusson G, Nordenstarn H (1972) Renal carcinoma (hypernephroma) occurring in 5 siblings. J Urol 108:58–61PubMedGoogle Scholar
  58. Freeman MR, Washecka R, Chung LW (1989) Aberrant expression of epidermal growth factor receptor and HER-2 (erbB-2) messenger RNAs in human renal cancers. Cancer Res 49:6221–6225PubMedGoogle Scholar
  59. Gamelin E, Mertins SD, Regis JT et al. (1999) Intrinsic drug resistance in primary and metastatic renal cell carcinoma. J Urol 162:217–224PubMedGoogle Scholar
  60. Gallou C, Longemeaux S, Delomenie C et al. (in press) Associations of GSTT1 non-null and NAT1 slow/rapid genotypes with VHL transversions in sporadic renal cell carcinoma. Pharmacogenetics in pressGoogle Scholar
  61. Glavac D, Neumann HP, Wittke C et al. (1996) Mutations in the VHL tumor suppressor gene and associated lesions in families with von Hippel-Lindau disease from central Europe. Hum Genet 98:271–280PubMedGoogle Scholar
  62. Glenn GM, Coyke PL, Zbar B, Linehan WM (1990) Von Hippel-Lindau disease. Clinical review and molecular genetics. Probl Urol 4:312–330Google Scholar
  63. Glenn GM, Daniel LN, Choyke P et al. (1991) Von Hippel-Lindau (VHL) disease: distinct phenotypes suggest more than one mutant allele at the VHL locus. Hum Genet 87:207–210PubMedGoogle Scholar
  64. Gnarra JR, Tory K, Weng Y et al. (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7:85–90PubMedGoogle Scholar
  65. Gnarra JR, Zhou S, Merrill MJ et al. (1996) Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 93:10589–10594PubMedCentralPubMedGoogle Scholar
  66. Gnarra JR, Ward JM, Porter FD et al. (1997) Defective placental vasculogenesis causes embryonic lethality in VHLdeficient mice. Proc Natl Acad Sci USA 94:9102–9107PubMedCentralPubMedGoogle Scholar
  67. Gorospe M, Egan JM, Zbar B et al. (1999) Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells. Mol Cell Biol 19:1289–1300PubMedCentralPubMedGoogle Scholar
  68. Grabmaier K, Vissers JL, De Weijert MC et al. (2000) Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 85:865–870PubMedGoogle Scholar
  69. Grawitz PA (1883) Die sogenannten Lipoma der Niere.Virchows Arch 93:39–63Google Scholar
  70. Green JS, Bowmer MI, Johnson GJ (1986) Von Hippel-Lindau disease in a Newfoundland kindred. CMAJ 134:133–146PubMedCentralPubMedGoogle Scholar
  71. Griffiths JR (1991) Are cancer cells acidic? Br J Cancer 64:425–427PubMedCentralPubMedGoogle Scholar
  72. Gross DJ, Avishai N, Meiner V, Filon D, Zbar B, Abeliovich D (1996) Familial pheochromocytoma associated with a novel mutation in the von Hippel-Lindau gene. J Clin Endocrinol Metab 81:147–149PubMedGoogle Scholar
  73. Groulx I, Bonicalzi ME, Lee S (2000) Ran-mediated nuclear export of the von Hippel-Lindau tumor suppressor protein occurs independently of its assembly with cullin-2. J Biol Chem 275:8991–9000PubMedGoogle Scholar
  74. Harris AL (2000) Von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy. Oncologist 5:32–36PubMedGoogle Scholar
  75. Henschler D, Vamvakas S, Lammert M et al. (1995) Increased incidence of renal cell tumors in a cohort of cardboard workers exposed to triehloroethene. Arch Toxicol 69:291–299PubMedGoogle Scholar
  76. Herman JG, Latif F, Weng Y et al. (1994) Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91:9700–9704PubMedCentralPubMedGoogle Scholar
  77. Hethcote HW, Knudson AG Jr (1978) Model for the incidence of embryonal cancers: application to retinoblastoma.Proc Natl Acad Sci USA 75:2453–2457PubMedCentralPubMedGoogle Scholar
  78. Hofstra RM, Landsvater RM, Ceccherini I et al. (1994) A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullarythyroid carcinoma. Nature 367:375–376PubMedGoogle Scholar
  79. Hosoe S, Brauch H, Latif F et al. (1990) Localization of the von Hippel-Lindau disease gene to a small region of chromosome 3. Genomies 8:634–640Google Scholar
  80. Huang LE, Gu J, Schau M, Bunn HF (1998) Regulation of hypoxia-inducible factor lalpha is mediated by an Ordependent degradation domain via the ubiquitin-protea-some pathway. Proc Natl Acad Sci USA 95:7987–7992PubMedCentralPubMedGoogle Scholar
  81. IARC IAfRoC (1987) IARC Monographs on the evaluation of carcinogenic risks to humans. Overall evaluations of carcinogenicity: an updating of IARC monographs Vols 1-42. IARC, Lyon, Suppl 7Google Scholar
  82. Idle JR, Armstrong M, Boddy AV et al. (1992) The pharmacogenetics of chemical carcinogenesis. Pharmacogenetics 2:246–258PubMedGoogle Scholar
  83. Iliopoulos O, Kibel A, Gray S, Kaelin WG (1995) Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1:822–826PubMedGoogle Scholar
  84. Ivanov SV, Kuzmin I, Wei MH et al. (1998) Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA 95:12596–12601PubMedCentralPubMedGoogle Scholar
  85. Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B (2000) Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 163:343–347PubMedGoogle Scholar
  86. Jeffers M, Rao MS, Rulong S et al. (1996) Hepatocyte growth factor/scatter factor-Met signaling induces proliferation, migration, and morphogenesis of pancreatic oval cells. Cell Growth Differ 7:1805–1813PubMedGoogle Scholar
  87. Jones AC, Daniells CE, Snell RG et al. (1997) Molecular genetic and phenotypic analysis reveals differences between TSC1 and TSC2 associated farnilial and sporadic tuberous sclerosis. Hum Mol Genet 6:2155–2161PubMedGoogle Scholar
  88. Kaelin G Jr (1999) Many vessels, faulty gene. Nature 399: 203–204PubMedGoogle Scholar
  89. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW (2000) Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 97:10430–10450PubMedCentralPubMedGoogle Scholar
  90. Kan YW, Dozy AM (1978) Polymorphism of DNA sequence adjacent to human beta-globin structural gene: relationship to sickle mutation. Proc Natl Acad Sci USA 75:5631–5635PubMedCentralPubMedGoogle Scholar
  91. Kenck C, Wilhelm M, Bugert P, Staehler G, Kovacs G (1996) Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas. J Pathol 179:157–161PubMedGoogle Scholar
  92. Kessler PM, Vasavada SP, Rackley RR et al. (1995) Expression of the Von Hippel-Lindau tumor suppressor gene, VHL, in human fetal kidney and during mouse embryogenesis. Mol Med 1:457–466PubMedCentralPubMedGoogle Scholar
  93. Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG Jr (1995) Binding of the von Hippel-Lindau tumor suppressor protein to Eiongin Band C. Science 269:1444–1446PubMedGoogle Scholar
  94. Kishida T, Yao M, Chen F, Orcutt ML, Lerman MI, Zbar B (1994) A novel donor splice site mutation associated with two mRNAs in von Hippel-Lindau disease. Hum Mol Genet 3:1191–1192PubMedGoogle Scholar
  95. Kishida T, Stackhouse TM, Chen F, Lerman MI, Zbar B (1995) Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations.Cancer Res 55:4544–4548PubMedGoogle Scholar
  96. Klein B, Weirich G, Brauch H (2001) DHPLC for germline mutation screening in the analysis of the VHL tumor suppressor gene: usefulness and limitations. Hum Genet108:376–384PubMedGoogle Scholar
  97. Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820–823PubMedCentralPubMedGoogle Scholar
  98. Kobayashi T, Hirayama Y, Kobayashi E, Kubo Y, Hino O (1995) A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer. Nat Genet 9:70–74PubMedGoogle Scholar
  99. Kovacs G (1989) Papillary renal cell carcinoma. A morphologic and cytogenetic study of 11 cases. Am J Pathol134:27–34PubMedCentralPubMedGoogle Scholar
  100. Kovacs G (1993a) Molecular cytogenetics of renal cell tumors. Adv Cancer Res 62:89–124PubMedGoogle Scholar
  101. Kovacs G (1993b) Molecular differential pathology of renal cell tumours. Histopathology 22:1–8PubMedGoogle Scholar
  102. Kovacs G, Szucs S, de Riese W, Baumgartel H (1987) Specific chromosome aberration in human renal cell carcinoma. Int J Cancer 40:171–178PubMedGoogle Scholar
  103. Kovacs G, Brusa P, de Riese W (1989a) Tissue-specific expression of a constitutional 3;6 translocation: development of multiple bilateral renal-cell carcinomas. Int J Cancer 43:422–427PubMedGoogle Scholar
  104. Kovacs G, Wilkens L, Papp T, de Riese W (1989b) Differentiation between papillary and nonpapillary renal cell carcinomas by DNA analysis. J Natl Cancer Inst 81:527–530PubMedGoogle Scholar
  105. Krek W (1998) Proteolysis and the Gl-S transition: the SCF connection. Curr Opin Genet Dev 8:36–42PubMedGoogle Scholar
  106. Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH (2000) Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19:5435–5443PubMedGoogle Scholar
  107. Kuzmin I, Duh FM, Latif F, Geil L, Zbar B, Lerman MI (1995) Identification of the promoter of the human von Hippel-Lindau disease tumor suppressor gene. Oncogene 10:2185–2194PubMedGoogle Scholar
  108. Lamiell JM, Salazar FG, Hsia YE (1989) Von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine (Baltimore) 68:1–29Google Scholar
  109. Latif F, Tory K, Gnarra J et al. (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene.Science 260:1317–1320PubMedGoogle Scholar
  110. Lerman M (2001) VHL protein function in health and disease.Wiley, New YorkGoogle Scholar
  111. Lerman MI, Latif F, Glenn GM et al. (1991) Isolation and regional localization of a large collection (2,000) of single-copy DNA fragments on human chromosome 3 for mapping and cloning tumor suppressor genes. Hum Genet 86:567–577PubMedGoogle Scholar
  112. Li FP, Marchetto DJ, Brown RS (1982) Familial renal carcinoma.Cancer Genet Cytogenet 7:271–275PubMedGoogle Scholar
  113. Li E, Beard C, Jaenisch R (1993) Role of DNA methylation in genomic imprinting. Nature 366:362–365PubMedGoogle Scholar
  114. Liao SY, Aurelio ON, Jan K, Zavada J, Stanbridge EJ (1997) Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney.Cancer Res 57:2827–2831PubMedGoogle Scholar
  115. Lieubeau-Teillet B, Rak J, Jothy S, Iliopoulos O, Kaelin W, Kerbel RS (1998) Von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res 58:4957–4962PubMedGoogle Scholar
  116. Lindau A (1926) Studien über Kleinhirnzysten. Bau, Pathogenese und Beziehungen zur Angiomatosis retinae. Acta Pathol Mierobiol Scand [Suppl I] p 1Google Scholar
  117. Linehan WM, Lerman MI, Zbar B (1995) Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer.JAMA 273:564–570PubMedGoogle Scholar
  118. Linehan WM, Shipley W, Parkinson D (1996) Cancer of the kidney and ureter. In: DeVita V.T., Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology.Lippincott, Philadelphia, p 19Google Scholar
  119. Lonergan KM, Iliopoulos O, Ohh M et al. (1998) Regulation of hypoxia-indueible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cu12. Mol Cell Biol 18:732–741PubMedCentralPubMedGoogle Scholar
  120. Longuemaux S, Delomenie C, Gallou C et al. (1999) Candidate genetic modifiers of individual susceptibility to renal cell careinoma: a study of polymorphie human xenobiotic-metabolizing enzymes. Cancer Res 59:2903–2908PubMedGoogle Scholar
  121. Luiten RM, Coney LR, Fleuren GJ, Warnaar SO, Litvinov SV (1996) Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma.Br J Cancer 74:735-744Google Scholar
  122. Maher ER, Yates JR, Harries R et al. (1990) Clinical features and natural history of von Hippel-Lindau disease. QJM 77:1151–1163PubMedGoogle Scholar
  123. Mai N, Qian C, Yokomizu A et al. (1998) Loss of imprinting and allele switch of p53 in renal cell carcinoma. Oncogene 17:1739–1741PubMedGoogle Scholar
  124. Mandel JS, McLaughlin JK, Schlehofer B et al. (1995) International renal-cell cancer study. IV. Occupation. Int J Cancer 61:601–605PubMedGoogle Scholar
  125. Manski TJ, Heffner DK, Glenn GM et al. (1997) Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. JAMA 277:1461–1466PubMedGoogle Scholar
  126. Matson MA, Cohen EP (1990) Acquired cystic kidney disease: occurrence, prevalence, and renal cancers. Medicine (Baltimore) 69:217–226Google Scholar
  127. Maxwell PH, Wiesener MS, Chang GW et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271–275PubMedGoogle Scholar
  128. McCredie M, Pommer W, McLaughlin JK et al. (1995) International renal-cell cancer study. II. Analgesies. Int J Cancer60:345–349PubMedGoogle Scholar
  129. McLaughlin JK, Blot WJ (1997) A critical review of epidemiology studies of triehloroethylene and perchloroethylene and risk of renal-cell cancer. Int Arch Occup Environ Health 70:222–231PubMedGoogle Scholar
  130. McLaughlin JK, Lindblad P, Mellemgaard A et al. (1995) International renal-cell cancer study. I. Tobacco use. Int J Cancer 60:194–198PubMedGoogle Scholar
  131. Mellemgaard A, Lindblad P, Schlehofer B et al. (1995) International renal-cell cancer study. III. Role of weight, height, physical activity, and use of amphetamines.Int J Cancer 60:350–354PubMedGoogle Scholar
  132. Melmon KL, Rosen SW (1964) Lindau’s disease: review of the literature and study of a large kindred. Am J Med 36:595–617PubMedGoogle Scholar
  133. Mickisch GH (1994) Chemoresistance of renal cell carcinoma: 1986-1994. World J Urol 12:214–223Google Scholar
  134. Miller MS, McCarver DG, Bell DA, Eaton DL, Goldstein JA (1997) Genetic polymorphisms in human drug metabolic enzymes. Fundam Appl Toxicol 40:1–14PubMedGoogle Scholar
  135. Moch HP, Sauter G, Buchholz N et al. (1996) Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. Cancer Res 56:27–30PubMedGoogle Scholar
  136. Moch H, Sauter G, Buchholz N et al. (1997) Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma. Hum Pathol 28:1255–1259PubMedGoogle Scholar
  137. Moch H, Sauter G, Gasser TC et al. (1998) EGF-r gene copy number changes in renal cell carcinoma detected by fluorescence in situ hybridization. J Pathol 184:424–429PubMedGoogle Scholar
  138. Morita R, Saito S, Ishikawa et al. (1991) Common regions of deletion on chromosomes 5q, 6q, and 10q in renal cell carcinoma. Cancer Res 51:5817–5820PubMedGoogle Scholar
  139. Mostofi FK (1981) Histological typing of kidney tumors. In: Mostofi FK (ed) International histological classification of tumours, vol 25. WHO, GenevaGoogle Scholar
  140. Motzer RJ, Russo P (2000) Systemic therapy for renal cell carcinoma. J Urol 163:408–417PubMedGoogle Scholar
  141. Motzer RJ, Bander NH, Nanus DM (1996) Renal-cell carcinoma. N Engl J Med 335:865–875PubMedGoogle Scholar
  142. Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S, Sukhatme VP (1997) The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 17:5629–5639PubMedCentralPubMedGoogle Scholar
  143. Müller M, Birner G, Dekant W (1998a) Reactivity of haloketenes and halothioketenes with nucleobases: chemical characterization of reaction products. Chem Res Toxicol 11:454–463PubMedGoogle Scholar
  144. Müller M, Birner G, Sander M, Dekant W (1998b) Reactivity of haloketenes and halothioketenes with nucleobases: reactions in vitro with DNA. Chem Res Toxicol 11:464–470PubMedGoogle Scholar
  145. Murphy WM, Beckwith JB, Farrow GM (1994) Atlas of tumor pathology, tumors of the kidney, bladder, and related urinary structures. Armed Forces Institute of Pathology, Washington DC, p 102Google Scholar
  146. Nagata H, Worobec AS, Oh CK et al. (1995) Identification of a point mutation in the catalytie domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 92:10560–10564PubMedCentralPubMedGoogle Scholar
  147. Naitoh J, Kaplan A, Dorey F, Figlin R, Belldegrun A (1999) Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy. J Urol 162:46–50PubMedGoogle Scholar
  148. Nebert DW, McKinnon RA, Puga A (1996) Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 15:273–280PubMedGoogle Scholar
  149. Neumann HP (1987a) Basic criteria for clinical diagnosis and genetic counselling in von Hippel-Lindau syndrome.Vasa 16:220–226PubMedGoogle Scholar
  150. Neumann HP (1987b) Prognosis of von Hippel-Lindau syndrome.Vasa 16:309–311PubMedGoogle Scholar
  151. Neumann HP, Wiestler OD (1991) Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet 337:1052–1054PubMedGoogle Scholar
  152. Neumann HP, Dinkel E, Brambs HJ et al. (1991) Pancreatic lesions in the von Hippel-Lindau syndrome. Gastroenterology 101:465–471PubMedGoogle Scholar
  153. Neumann HP, Eng C, Mulligan LM et al. (1995) Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II. JAMA 274:1149–1151PubMedGoogle Scholar
  154. Oda H, Kume H, Shimizu Y, Inoue T, Ishikawa T (1998) Loss of imprinting of igf 2 in renal-cell carcinomas. Int J Cancer 75:343–346PubMedGoogle Scholar
  155. Ogawa O, Kakehi Y, Ogawa K, Koshiba M, Sugiyama T, Yoshida O (1991) Allelic loss at chromosome 3p characterizes clear cell phenotype of renal cell carcinoma. Cancer Res 51:949–953PubMedGoogle Scholar
  156. Ohh M, Yauch RL, Lonergan KM et al. (1998) The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1:959–968PubMedGoogle Scholar
  157. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ et al. (1986) Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 38:489–494PubMedGoogle Scholar
  158. Pagliaro L, Daliani D, Amato R et al. (2000) A phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer 89:615–618PubMedGoogle Scholar
  159. Pal S, Claffey KP, Dvorak HF, Mukhopadhyay D (1997) The von Hippel-Lindau gene product inhibits vascular perme-ability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J Biol Chem 272:27509–27512PubMedGoogle Scholar
  160. Paradis V, Lagha NB, Zeimoura L et al. (2000) Expression of vascular endothelial growth factor in renal cell carcinomas. Virchows Arch 436:351–356PubMedGoogle Scholar
  161. Park M, Dean M, Kaul K, Braun MJ, Gonda MA, Vande Woude G (1987) Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc Natl Acad Sci USA 84:6379–6383PubMedCentralPubMedGoogle Scholar
  162. Parkin DM, Muir CS (1992) Cancer incidence in five continents. Comparability and quality of data. IARC Sci Publ 120:45–173PubMedGoogle Scholar
  163. Pathak S, Strong LC, Ferrell RE, Trindade A (1982) Familial renal cell carcinoma with a 3;11 chromosome translocation limited to tumor cells. Science 217:939–941PubMedGoogle Scholar
  164. Pause A, Lee S, Worrell RA et al. (1997) The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci USA 94:2156–2161PubMedCentralPubMedGoogle Scholar
  165. Pause A, Lee S, Lonergan KM, Klausner RD (1998) The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci USA 95:993–998PubMedCentralPubMedGoogle Scholar
  166. Pearson HH (1969) Familial renal tumours. Aust N Z J Surg 38:333–338PubMedGoogle Scholar
  167. Pesch B, Haerting J, Ranft U, Klimpel A, Oelschlagel B, Schill W (2000) Occupational risk factors for renal cell carcinoma: agent-specific results from a case-control study in Germany. Int J Epidemiol 29:1014–1024PubMedGoogle Scholar
  168. Phillips E, Messing EM (1993) Role of lymphadenectomy in the treatment of renal cell carcinoma. Urology 41:9–15PubMedGoogle Scholar
  169. Poston CD, Jaffe GS, Lubensky IA et al. (1995) Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular genetic implications. J Urol 153:22–26PubMedGoogle Scholar
  170. Press GA, McClennan BL, Melson GL, Weyman PJ, Mauro MA, Lee JK (1984) Papillary renal cell carcinoma: CT and sonographic evaluation. AJR Am J Roentgenol 143:1005–1009PubMedGoogle Scholar
  171. Puga A, Nebert DW, McKinnon RA, Menon AG (1997) Genetic polymorphisms in human drug-metabolizing enzymes: potential uses of reverse genetics to identify genes of toxicological relevance. Crit Rev Toxicol 27:199–222PubMedGoogle Scholar
  172. Pugh CW, O’Rourke JF, Nagao M, Gleadle JM, Ratcliffe PJ (1997) Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit. J Biol Chem 272:11205–11214PubMedGoogle Scholar
  173. Ramp U, Reinecke P, Gabbert HE, Gerharz CD (2000) Differential response to transforming growth factor (TGF)-alpha and fibroblast growth factor (FGF) in human renal cell carcinomas of the clear cell and papillary types. Eur J Cancer 36:932–941PubMedGoogle Scholar
  174. Richards FM, Schofield PN, Fleming S, Maher ER (1996) Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. Hum Mol Genet 5:639–644PubMedGoogle Scholar
  175. Robson CJ, Churchill BM, Anderson W (1969) The results of radical nephrectomy for renal cell carcinoma. J Urol 101:297–301PubMedGoogle Scholar
  176. Roth JS, Rabinowitz AD, Benson M, Grossman ME (1993) Bilateral renal cell carcinoma in the Birt-Hogg-Dube syndrome. J Am Acad Dermatol 29:1055–1056PubMedGoogle Scholar
  177. Russo P (2000) Renal cell carcinoma: presentation, staging, and surgical treatment. Semin Oncol 27:160–176PubMedGoogle Scholar
  178. Sahin U, Tureci O, Schmitt H et al. (1995) Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92:11810–11813PubMedCentralPubMedGoogle Scholar
  179. Salceda S, Caro J (1997) Hypoxia-inducible factor 1a1pha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272:22642–22647PubMedGoogle Scholar
  180. Sampson JR (1996) The kidney in tuberous sclerosis: manifestations and molecular genetic mechanisms. Nephrol Dial Transplant 11:34–37PubMedGoogle Scholar
  181. Sato K, Tsuchiya N, Sasaki R et al. (1999) Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma. Jpn J Cancer Res 90:874–879PubMedGoogle Scholar
  182. Schlehofer B, Pommer W, Mellemgaard A et al. (1996) International renal-cell-cancer study. VI. The role of medical and family history. Int J Cancer 66:723–726PubMedGoogle Scholar
  183. Schlessinger J, Ullrich A (1992) Growth factor signaling by receptor tyrosine kinases. Neuron 9:383–391PubMedGoogle Scholar
  184. Schmidt L, Duh FM, Chen F et al. (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68–73PubMedGoogle Scholar
  185. Schmidt L, Junker K, Nakaigawa N et al. (1999) Novel mutations of the MET proto-oncogene in papillary renal carcinomas.Oncogene 18:2343–2350PubMedGoogle Scholar
  186. Schoenfeld AR, Parris T, Eisenberger A et al. (2000) The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis. Oncogene 19:5851–5857PubMedGoogle Scholar
  187. Schulz WA (1998) DNA methylation in urological malignancies.Int J Oncol 13:151–167PubMedGoogle Scholar
  188. Seizinger BR, Rouleau GA, Ozelius LJ et al. (1988) Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 332:268–269PubMedGoogle Scholar
  189. Semenza GL (1998) Hypoxia-inducible factor 1 and the molecular physiology of oxygen homeostasis. J Lab Clin Med 131:207–214PubMedGoogle Scholar
  190. Shuin T, Kondo K, Torigoe S et al. (1994) Frequent somatic mutations and loss of heterozygosity of the von HippelLindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 54:2852–2855PubMedGoogle Scholar
  191. Siemeister G, Weindei K, Mohrs K, Barleon B, Martiny-Baron G, Marme D (1996) Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 56:2299–2301PubMedGoogle Scholar
  192. Solomon E, Bodmer WF (1979) Evolution of sickle variant gene. Lancet 1:923PubMedGoogle Scholar
  193. Stebbins CE, Kaelin WG Jr, Pavletich NP (1999) Structure of the VHL-Elongin C-Elongin B complex: implications for VHL tumor suppressor function. Science 284:455–461PubMedGoogle Scholar
  194. Steinbach F, Stöckle M, Riedmiller H, Weingartner K, Hohenfellner R (1991) Tumor enucleation of renal cell carcinoma: operative technique, DNA cytometry results, complications. Prog Clin Biol Res 370:1–7PubMedGoogle Scholar
  195. Steinbach F, Stöckle M, Müller SC et al. (1992) Conservative surgery of renal cell tumors in 140 patients: 21 years of experience. J Urol 148:24–30PubMedGoogle Scholar
  196. Steinbach F, Stöckle M, Griesinger A et al. (1994) Multifocal renal cell tumors: a retrospective analysis of 56 patients treated with radical nephrectomy. J Urol 152:1393–1396PubMedGoogle Scholar
  197. Stolle C, Glenn G, Zbar B et al. (1998) Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 12:417–423PubMedGoogle Scholar
  198. Störkel S, Keymer R, Steinbach F, Thoenes W (1992) Reaction patterns of tumor infiltrating lymphocytes in different renal cell carcinomas and oncocytomas. Prog Clin Biol Res 378:217–223PubMedGoogle Scholar
  199. Störkel S, Eble JN, Adlakha K et al. (1997) Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80:987–989PubMedGoogle Scholar
  200. Sugimura K, Yoshida N, Hisatomi H, Nakatani T, Ikemoto S (1999) Telomerase in human renal cell carcinoma. B J Urol Int 83:693–697Google Scholar
  201. Teh BT, Giraud S, Sari NF et al. (1997) Familial non-VHL non-papillary clear-cell renal cancer. Lancet 349:848–849PubMedGoogle Scholar
  202. Thoenes W, Störkel S, Rumpelt HJ (1986) Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics.Pathol Res Pract 181:125–143PubMedGoogle Scholar
  203. Thoenes W, Störkel S, Rumpelt HJ, Moll R (1990) Cytomorphological typing of renal cell carcinoma-a new approach. Eur Urol 18:6–9PubMedGoogle Scholar
  204. Tisherman SE, Tisherman BG, Tisherman SA, Dunmire S, Levey GS, Mulvihill JJ (1993) Three-decade investigation of familial pheochromocytoma. An allele of von HippelLindau disease? Arch Intern Med 153:2550–2556PubMedGoogle Scholar
  205. Tomisawa M, Tokunaga T, Oshika Y et al. (1999) Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer 35:133–137PubMedGoogle Scholar
  206. Toro JR, Glenn G, Duray P et al. (1999) Birt-Hogg-Dube syndrome: a novel marker of kidney neoplasia. Arch Dermatol 135: 1195–1202PubMedGoogle Scholar
  207. Tory K, Brauch H, Linehan M et al. (1989) Specific genetic change in tumors associated with von Hippel-Lindau disease. J Natl Cancer Inst 81:1097–1101PubMedGoogle Scholar
  208. Ullrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61:203–212PubMedGoogle Scholar
  209. Vamvakas S, Bruning T, Thomasson B et al. (1998) Renal cell cancer correlated with occupational exposure to trichloroethene.J Cancer Res Clin Oncol 124:374–382PubMedGoogle Scholar
  210. Van den Berg E, Oosterhuis JW, Störkel S et al. (1994) Pathogenesis of renal cell tumors: a cytogenetic model. 44th European Workshop on Cytogenetics and Molecular Genetics of Human Solid Tumors, Noordwijkerhout, The Netherlands, A:45Google Scholar
  211. Van der Hout AH, Brown RS, Li PP, Buys CH (1991) Localization by in situ hybridization of three 3p probes with respect to the breakpoint in a t(3;8) in hereditary renal cell carcinoma. Cancer Genet Cytogenet 51:121–124PubMedGoogle Scholar
  212. Van Slegtenhorst M, Hoogt de R, Hermans C et al. (1997) Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277:805–808PubMedGoogle Scholar
  213. Vogelzang NJ, Stadler WM (1998) Kidney cancer. Lancet 352:1691–1696PubMedGoogle Scholar
  214. Volkel W, Dekant W (1998) Chlorothioketene, the ultimate reactive intermediate formed by cysteine conjugate betalyase-mediated cleavage of the trichloroethene metabolite S-(1,2-Dichlorovinyl)-L-cysteine, forms cytosine adducts in organic solvents, but not in aqueous solution. Chem Res Toxicol 11:1082–1088PubMedGoogle Scholar
  215. Volm M, Pommerenke EW, Efferth T, Lohrke H, Mattern J (1991) Circumvention of multi-drug resistance in human kidney and kidney carcinoma in vitro. Cancer 67:2484–2489PubMedGoogle Scholar
  216. Von Hippel E (1904) über eine seltene Erkrankung der Netzhaut. Graefes Arch Ophthalmol 59:83–106Google Scholar
  217. Walther MM, Lubensky IA, Venzon D, Zbar B, Linehan WM (1995) Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von HippelLindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. J Urol 154:2010–2015PubMedGoogle Scholar
  218. Wang N, Perkins KL (1984) Involvement of band 3p14 in t(3;8) hereditary renal carcinoma. Cancer Genet Cytogenet 11:479–481PubMedGoogle Scholar
  219. Warburg O (1926) über den Stoffwechsel von Tumoren. Cambridge University Press, CambridgeGoogle Scholar
  220. Washecka R, Hanna M (1991) Malignant renal tumors in tuberous sclerosis. Urology 37:340–343PubMedGoogle Scholar
  221. Wechsel HW, Bichler KH, Feil G, Loeser W, Lahme S, Petri E (1999) Renal cell carcinoma: relevance of angiogenetic factors. Anticancer Res 19:1537–1540PubMedGoogle Scholar
  222. Weidner U, Peter S, Strohmeyer T, Hussnatter R, Ackermann R, Sies H (1990) Inverse relationship of epidermal growth factor receptor and HER2/neu gene expression in human renal cell carcinoma. Cancer Res 50:4504–4509PubMedGoogle Scholar
  223. Weidner KM, Sachs M, Birchmeier W (1993) The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. J Cell Biol 121:145–154PubMedGoogle Scholar
  224. Wenger RH, Gassmann M (1997) Oxygen(es) and the hypoxia-inducible factor-1. Biol Chem 378:609–616PubMedGoogle Scholar
  225. Whaley JM, Naglich J, Gelbert L et al. (1994) Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma [published erratum appears in Am J Hum Genet 56:356]. Am J Hum Genet 55:1092–1102PubMedCentralPubMedGoogle Scholar
  226. Yao M, Latif F, Orcutt ML et al. (1993) Von Hippel-Lindau disease: identification of deletion mutations by pulsed field gel electrophoresis. Hum Genet 92:605–614PubMedGoogle Scholar
  227. Ye Y, Vasavada S, Kuzmin I, Stackhouse T, Zbar B, Williams BR (1998) Subcellular localization of the von Hippel-Lindau disease gene product is cell cycle-dependent. Int J Cancer 78:62–69PubMedGoogle Scholar
  228. Yeung RS, Xiao GH, Jin F, Lee WC, Testa JR, Knudson AG (1994) Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene. Proc Natl Acad Sci USA 91:11413–11416PubMedCentralPubMedGoogle Scholar
  229. Yoshida K, Tosaka A (1994) Epidermal growth factor binding by membranes of human renal cell carcinomas: establishment of an epidermal growth factor receptor assay for clinical use. Int J Urol 1:319–323PubMedGoogle Scholar
  230. Yoshida K, Hosoya Y, Sumi S et al. (1997) Studies of the expression of epidermal growth factor receptor in human renal cell carcinoma: a comparison of immunohistochemical method versus ligand bin ding assay. Oncology 54:220–225PubMedGoogle Scholar
  231. Yu DS, Chang SY, Ma CP (1998) The expression of mdr-1-related gp-170 and its correlation with anthracycline resistance in renal cell carcinoma cell lines and multidrugresistant sublines. Br J Urol 82:544–547PubMedGoogle Scholar
  232. Yu DS, Sun GH, Ma CP, Chang SY (1999) Cocktail modulator mixtures for overcoming multidrug resistance in renal cell carcinoma. Urology 54:377–381PubMedGoogle Scholar
  233. Zbar B (1995) Von Hippel-Lindau disease and sporadic renal cell carcinoma. Cancer Surv 25:219–232PubMedGoogle Scholar
  234. Zbar B, Lerman M (1998) Inherited carcinomas of the kidney. Adv Cancer Res 75:163–201PubMedGoogle Scholar
  235. Zbar B, Brauch H, Talmadge C, Linehan M (1987) Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 327:721–724PubMedGoogle Scholar
  236. Zbar B, Tory K, Merino M et al. (1994) Hereditary papillary renal cell carcinoma. J Urol 151:561–566PubMedGoogle Scholar
  237. Zbar B, Glenn G, Lubensky I et al. (1995a) Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J Urol 153:907–912PubMedGoogle Scholar
  238. Zbar B, Glenn G, Lubensky I et al. (1995b) Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J Urol 153:907–912PubMedGoogle Scholar
  239. Zbar B, Kishida T, Chen F et al. (1996) Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat8:348–357PubMedGoogle Scholar
  240. Zhuang Z, Park WS, Pack S et al. (1998) Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet 20:66–69PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • Jochen Decker
  • Hiltrud Brauch

There are no affiliations available

Personalised recommendations